These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 28540165)

  • 1. Nanotechnology-based strategies for treatment of ocular disease.
    Weng Y; Liu J; Jin S; Guo W; Liang X; Hu Z
    Acta Pharm Sin B; 2017 May; 7(3):281-291. PubMed ID: 28540165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems.
    Juliana FR; Kesse S; Boakye-Yiadom KO; Veroniaina H; Wang H; Sun M
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31652593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions.
    Lalu L; Tambe V; Pradhan D; Nayak K; Bagchi S; Maheshwari R; Kalia K; Tekade RK
    J Control Release; 2017 Dec; 268():19-39. PubMed ID: 28756272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.
    Onugwu AL; Nwagwu CS; Onugwu OS; Echezona AC; Agbo CP; Ihim SA; Emeh P; Nnamani PO; Attama AA; Khutoryanskiy VV
    J Control Release; 2023 Feb; 354():465-488. PubMed ID: 36642250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases.
    Bachu RD; Chowdhury P; Al-Saedi ZHF; Karla PK; Boddu SHS
    Pharmaceutics; 2018 Feb; 10(1):. PubMed ID: 29495528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular drug delivery systems: An overview.
    Patel A; Cholkar K; Agrahari V; Mitra AK
    World J Pharmacol; 2013; 2(2):47-64. PubMed ID: 25590022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent perspectives on the delivery of biologics to back of the eye.
    Joseph M; Trinh HM; Cholkar K; Pal D; Mitra AK
    Expert Opin Drug Deliv; 2017 May; 14(5):631-645. PubMed ID: 27573097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.
    Cholkar K; Patel A; Vadlapudi AD; Mitra AK
    Recent Pat Nanomed; 2012; 2(2):82-95. PubMed ID: 25400717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Nanotherapies for the Posterior Segment of the Eye: An Integrative Review on Recent Advancements and Challenges.
    Gogoi NR; Marbaniang D; Pal P; Ray S; Mazumder B
    Pharm Nanotechnol; 2022 Nov; 10(4):268-278. PubMed ID: 35946098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related ocular conditions: Current treatments and role of cyclodextrin-based nanotherapies.
    Lorenzo-Veiga B; Alvarez-Lorenzo C; Loftsson T; Sigurdsson HH
    Int J Pharm; 2021 Jun; 603():120707. PubMed ID: 33991594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chitosan-based nanostructures: a delivery platform for ocular therapeutics.
    de la Fuente M; Raviña M; Paolicelli P; Sanchez A; Seijo B; Alonso MJ
    Adv Drug Deliv Rev; 2010 Jan; 62(1):100-17. PubMed ID: 19958805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimally invasive microneedles for ocular drug delivery.
    Thakur Singh RR; Tekko I; McAvoy K; McMillan H; Jones D; Donnelly RF
    Expert Opin Drug Deliv; 2017 Apr; 14(4):525-537. PubMed ID: 27485251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Drug Delivery: Present Innovations and Future Challenges.
    Gote V; Sikder S; Sicotte J; Pal D
    J Pharmacol Exp Ther; 2019 Sep; 370(3):602-624. PubMed ID: 31072813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Biodegradable Nano-Sized Polymer-Based Ocular Drug Delivery.
    Lynch C; Kondiah PPD; Choonara YE; du Toit LC; Ally N; Pillay V
    Polymers (Basel); 2019 Aug; 11(8):. PubMed ID: 31434273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanocarriers in ocular drug delivery: an update review.
    Wadhwa S; Paliwal R; Paliwal SR; Vyas SP
    Curr Pharm Des; 2009; 15(23):2724-50. PubMed ID: 19689343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of nanotechnology in control of human diseases: perspectives in ocular surface diseases.
    Rai M; Ingle AP; Gaikwad S; Padovani FH; Alves M
    Crit Rev Biotechnol; 2016 Oct; 36(5):777-87. PubMed ID: 26189355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.
    Bisht R; Mandal A; Jaiswal JK; Rupenthal ID
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Mar; 10(2):. PubMed ID: 28425224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.
    Agrahari V; Agrahari V; Mandal A; Pal D; Mitra AK
    Expert Opin Drug Deliv; 2017 Oct; 14(10):1145-1162. PubMed ID: 27967247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems.
    Wu KY; Joly-Chevrier M; Akbar D; Tran SD
    Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current nanotechnological strategies for treating glaucoma.
    Goyal G; Garg T; Rath G; Goyal AK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(5):365-405. PubMed ID: 25271557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.